Mariam Mansour Staff Profile

December 5, 2024

Prescient Therapeutics: Mariam Mansour, PhD

Mariam Mansour, PhD, Director of Clinical Development and Translational Sciences at Prescient, shares insights into PTX’s therapy portfolio, her experience so far, and her vision for the company’s future.

In this video, Mariam discusses:

  • Why she believes Prescient is delivering impactful benefits, having moved beyond the “fishing expedition” phase.
  • Her role in PTX’s CellPryme program and the promising results achieved so far.
  • Her vision for Prescient, bolstered by the successful PTX-100 Phase 1b trial outcomes, a solid foundation, and growing momentum.

Recorded on 5 December 2024 at 2pm (AEDT)

Join the next Prescient Therapeutics webcast

Register to stay up to date with Prescient Therapeutics

Featured Speaker

Mariam Mansour, PhD

Director of Clinical Development and Translational Sciences

With over 17 years of experience in clinical development, Mariam Monsour, PhD, is an accomplished expert in biologics, gene, and cell therapies. Formerly the Research and Clinical Lead at CSL and a Senior Research Fellow at Peter MacCallum Cancer Centre, she has driven immuno-oncology advancements and led preclinical development initiatives for early-stage portfolio assets at Bristol Myers Squibb and Genentech. Her extensive expertise includes developing therapeutic portfolio strategies, managing clinical pipelines, and implementing biomarker and bioanalytical strategies to support nonclinical, GLP toxicology, pharmacology, and GCP clinical studies.

Related Post

This investor centre was built by Reach Markets

©2022 Reach Markets

×

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
×

Any advice is general only

Any advice provided by Reach Markets, the Lead Manager on this offer, including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice.

×

Receive email updates

What is a 708 investor?

By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.